First 'photo-drug' for pain can be activated with light

Image
Press Trust of India London
Last Updated : Apr 12 2017 | 5:23 PM IST
Researchers have designed the first "photo-drug" to treat pain that can be specifically activated with light at any moment.
Common pharmacology can limit the therapeutic action of any drug, said researchers, including those from University of Barcelona in Spain.
Using light on a photosensitive drug, the pharmacological process can be controlled with spatial and temporal precision, they said.
The drug JF-NP-26 has powerful therapeutic applications to treat pain and can be specifically activated at any moment with light.
"In the clinical field, there is not any precedent of the uses of optopharmacology to improve pain treatment or any disease associated with the nervous system. This is the first light-activated drug designed for the treatment of pain in vivo with animal models," said Francisco Ciruela, Professor at University of Barcelona.
In the new optopharmacology proposal published in the journal eLife, a drug with a known action mechanism (for example an analgesic) is chemically modified to make it photosensitive and inactive.
This drug is activated when receiving light - using an optical fibre - of a suitable wave length and with an exact precision on the target tissue (brain, skin, articulations, etc).
Compared to other photosensitive compounds, JF-NP-26 is a molecule that has no pharmacological effect on an animal until the target tissue received light from a visible spectrum (405 nm wave length).
Moreover, JF-NP-26 does not show toxic or unwanted effects even if the dose is high, researchers said.
The drug's lightening includes a treatment on the molecule that releases the active molecule (raseglurant) that blocks the metabotropic glutamate type 5 (mGlu5) receptor, found in lots of neuronal functions such as the spread of neuronal pain.
Blocking this receptor allows preventing the pain from spreading into the brain. This can be produced both due the outlying neurons and the central nervous system (brain) and create, in both cases, an analgesic effect as a result.
"The molecule created by the action of the light, the raseglurant, does not belong to any group of drugs from the classic anti-pain list of drugs: non-steroidal anti- inflammatory drugs or NSAID (paracetamol, ibuprofen, etc) and opioids (morphine, phentanyl).
"Consequently, the study describes an analgesic mechanism which has not been explored enough so far," said Ciruela.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 12 2017 | 5:23 PM IST

Next Story